JP: Let's assume the LPC model with Elite is what
Post# of 30028
Posted On: 08/29/2014 4:39:13 PM
JP: Let's assume the LPC model with Elite is what we are patterned after, as you've indicated. What happens from here? To make the pps go from .122 cents to above .50 or .60 cents, some kind of SQUEEZE must happen when good news hits. I'm assuming LPC and their arms length affiliates have a handle on the OS at AMBS and know what the available float is. With that knowledge and their past experience in these type of things, you would think they'd know how to create a SQUEEZE upon the announcement of our 3 LymPro catalysts: 1) Revenue Guidance, 2) Data, & 3) Partnership.
Does LPC & affiliates start buying more to create the squeeze as soon as news comes? We had Money Runners help run up the pps prior to July 31st. That didn't work out so well.
How do you see this going so that LPC helps us up list at a higher price, without dropping 30 to 50% afterward? Gerald mentioned just a week or so ago that they had plans in place to stimulate the pps even after the up listing. But, if we go from .12 cents to .60 cents in 3 months....that's a steep climb! I wonder how we stay up there?
JP Morgan & Fidelity and other institutional investors will hopefully be buying the shares at .60 cents that LPC is selling, but it's hard to predict it will work like that. MANF and Eltoprazine catalysts will also help. But we might have a LymPro lull after commercialization for 6 months while we're waiting for Revenue ramp up. Gerald and LPC must have some sort of understanding where we don't get dumped.
Does LPC & affiliates start buying more to create the squeeze as soon as news comes? We had Money Runners help run up the pps prior to July 31st. That didn't work out so well.
How do you see this going so that LPC helps us up list at a higher price, without dropping 30 to 50% afterward? Gerald mentioned just a week or so ago that they had plans in place to stimulate the pps even after the up listing. But, if we go from .12 cents to .60 cents in 3 months....that's a steep climb! I wonder how we stay up there?
JP Morgan & Fidelity and other institutional investors will hopefully be buying the shares at .60 cents that LPC is selling, but it's hard to predict it will work like that. MANF and Eltoprazine catalysts will also help. But we might have a LymPro lull after commercialization for 6 months while we're waiting for Revenue ramp up. Gerald and LPC must have some sort of understanding where we don't get dumped.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼